CoChat

Congenital Adrenal Hyperplasia—More Dogma Bites the Dust

Auchus, Richard J., Miller, Walter L. · 2012 · The Journal of Clinical Endocrinology & Metabolism
Cited by 22

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Congenital adrenal hyperplasia (CAH) has fascinated physicians and sociologists at least since 1865, when de Crecchio published his famous autopsy and social report of a person whose sex of rearing was ambivalent in early childhood and who lived as a man, died in an apparent Addisonian crisis, and was found to have hyperplastic adrenals, a uterus, fallopian tubes, and ovaries at autopsy (described in Ref. 1). The hormonal basis of CAH was elucidated in the 1950s, illustrating the transition of endocrinology from descriptive clinical phenomenology to a biochemically based understanding of physiology and disease (reviewed by Ref. 1). This era employed the available crude tools and analytical chemistry to separate, isolate, and characterize steroids from blood and urine. Until recently, much confusion pervaded the literature on adrenal steroidogenesis and its disorders because only a limited number of circulating steroids could be measured by immunoassays. With the advent of radiolabeled steroids in pure form, isotope-tracing technology provided a glimpse of steroid pathways and metabolic flux (2), but the array of steroid biosynthetic and degradative enzymes was unknown, and the substantial differences in steroidogenesis among different mammals were not appreciated. Cytochrome P450 was described in 1962, and the first activity ascribed to P450 enzymes was steroid 21-hydroxylation (3), but it took another decade before it became clear that there were many distinct P450 enzymes participating in steroidogenesis. The advent of molecular cloning technologies in the 1980s rapidly permitted the identification of the various steroidogenic genes and their encoded enzymes (4). Today, we have a very detailed understanding of the molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders (5), yet the discovery of new diseases and pathways of steroidogenesis constantly forces us to revise our ideas and to scrap some long-standing dogma. Now, with parallel advances in mass spectrometrometric methods for comprehensive steroid analysis (6), we have come full circle, and steroid chemistry has regained center stage. In this issue of the JCEM, Kamrath et al. (7) show how advanced technologies applied to urinary steroid analysis—coupled with a broader understanding of the pathways of androgen synthesis—are revising how we conceptualize the origin of androgen excess in CAH. The methodologies employed in this work and the insight gained from the data provide new analytes (biomarkers) that should improve the diagnosis of CAH and the management of this complex disorder. Steroid 21-hydroxylase deficiency (21OHD), which accounts for approximately 95% of the cases of CAH, is caused by mutations in the CYP21A2 gene encoding the adrenal 21-hydroxylase, P450c21 (5). For most of the past 50 yr, the general understanding of this disorder has been that the defective 21-hydroxylase prevents the fetus from producing cortisol, leading to overproduction of ACTH, which then drives adrenal steroidogenesis. In the presence of the block in 21-hydroxylation, however, 17-hydroxyprogesterone (17OHP) accumulates and is then converted to “adrenal androgens.” Pathways in textbooks traditionally showed 17OHP being the principal (or only) precursor of androstenedione, which was regarded as being an androgen as well as being the principal precursor of testosterone. Consequently, the prevailing assumption has been that, in 21OHD, adrenal-derived androstenedione and testosterone are the proximate precursors to dihydrotestosterone (DHT), the critical androgen for virilization of the external genitalia, and that the last step is mediated by steroid 5α-reductase type 2, as in normal boys. As a result of this model for the mechanism of virilization in 21OHD, there has been tremendous focus on 17OHP; this steroid has long been used to diagnose CAH and to monitor its treatment, despite well-documented shortcomings in this use (8). The main problem with this traditional model is that we have known for over 20 yr that the human 17-hydroxylase/17,20-lyase (P450c17) cannot convert 17OHP to androstenedione (Δ4 pathway) to any appreciable extent (9, 10), and it was not until recently that 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5, AKR1C3) was shown to convert androstenedione to testosterone in the human fetal adrenal (11, 12), although conversion of dehydroepiandrosterone (DHEA) to androst-5-ene-3β,17β-diol (A5diol) and then to testosterone is at least equally likely (5). If 17OHP conversion to androstenedione is poor, then DHEA and A5diol (Δ5 pathway) might be the major 19-carbon steroids produced by the adrenal in 21OHD, which are then metabolized to DHT by peripheral enzymes. The difficulty with this view is that the fetal adrenal normally produces abundant DHEA sulfate, and any androstenedione and testosterone formed after about 20 wk gestation is normally converted to estrogen in the placenta, defending the female fetus from vir

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-1080

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Auchus, R. J., & Miller, W. L.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-03-01
Volume
97
Issue
3
Pages
772-775
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2042831623
Cited by
22
References
13
FWCI
1.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.